Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

Segment Information

The Company manages its operations as a single segment. The Company’s CODM, its Chief Executive Officer, manages the Company's operations on a consolidated basis for the purposes of assessing performance and making operating decisions. The segment measure of profit or loss is consolidated net income (loss).

The following table presents selected financial information with respect to the Company's single operating segment for the years ended:

	Year Ended December 31,
	2024		2023
Collaboration revenue	$	210,782	$	129,013
Less:
Research and development expenses
Direct research and development expenses
ENTR-601-44	13,109		10,043
ENTR-601-45	8,584		9,782
ENTR-601-50	10,851		3,016
ENTR-601-51	1,345		1,531
Collaboration services	12,074		11,970
Other preclinical and discovery	7,926		6,712
Unallocated research and development expenses
Personnel related (including stock-based compensation)	41,762		31,250
Facility related and other	29,655		25,580
Total research and development expenses	125,306		99,884
General and administrative expenses	38,465		32,291
Interest and other income	19,474		15,218
Provision for income taxes	(859)		(18,741)
Net income (loss)	$	65,626	$	(6,685)

Assets regularly provided to the CODM are consistent with those reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash, cash equivalents and marketable securities balances. All of the Company’s tangible assets are held in the United States.